Epidermolysis bullosa (EB) comprises a heterogeneous group of rare genetic disorders characterized by skin and mucosal fragility, leading to recurrent blistering, chronic wounds, and significant morbidity. Recent advances have led to the approval of several EB‐specific wound treatments, allowing patients, caregivers, and healthcare practitioners a broader arsenal to improve disease management and outcomes. This includes birch triterpenes (also known as birch bark extract or Oleogel‐S10), a topical gel containing 10% birch triterpene extract combined with sunflower oil. Here, we consolidate the real‐world clinical experience from 12 EB specialists who treated over 140 patients with birch triterpenes in centers across Europe and the USA. Experience in patients treated with birch triterpenes spans both pediatric and adult populations diagnosed with junctional EB and dominant/recessive dystrophic EB, and with both acute and chronic wounds. The authors address patient‐ and wound‐specific considerations, treatment application, removal, and duration, as well as integration with other treatments. The authors, in addition, provide actionable guidance for optimizing treatment regimens, managing patient and caregiver expectations, and addressing challenges related to real‐world use of birch triterpenes. The importance of patient education and treatment adherence, as well as assessing functional outcomes, such as pain reduction, improved mobility, and quality of life measures in the evaluation of treatment effectiveness, are also discussed. This review seeks to contextualize the evidence derived from clinical trials with the realities of routine clinical practice, equipping healthcare practitioners to provide care that is both evidence‐based and attuned to the unique needs of individuals living with EB.